Aviragen Therapeutics (AVIR) Misses Q3 EPS by 11c
Tweet
Share
E-mailGet Alerts AVIR Hot Sheet
Join SI Premium – FREE
Aviragen Therapeutics (NASDAQ: AVIR) reported Q3 EPS of ($0.53), $0.11 worse than the analyst estimate of ($0.42).
For earnings history and earnings-related data on Aviragen Therapeutics (AVIR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Barclays Upgrades 1&1 AG (1U1:GR) to Overweight
- Nomura/Instinet Resumes Toyota Tsusho Corp (8015:JP) at Buy
- Blackberry earnings preview Q1: strong print expected, AI potential in focus
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
